Last Updated: July 10, 2026
When choosing a GLP-1 provider, the "best" option depends entirely on whether you are navigating the complexities of commercial insurance for a brand-name pen or seeking the predictable, flat-rate pricing of a compounding specialist.
In this side-by-side comparison, we analyze two of the industry’s most respected platforms: PlushCare, a legacy primary-care telehealth leader, and Mochi Health, a specialized weight-management program known for its "Best Value" designation. Both providers reside in our Top Tier category, but they serve two very different patient profiles.
Quick Comparison Table (2026)
| Feature | PlushCare | Mochi Health |
|---|---|---|
| GLP-1.Reviews Score | 4.6 / 5.0 (Top Tier) | 4.8 / 5.0 (Top Tier) |
| Monthly Membership | $19.99/mo | $79/mo ($39 first month promo) |
| Visit Fee | $129 per visit | Included in membership |
| Insurance Accepted | Yes (Meds & Visits) + Medicare | Self-pay (meds); brand-name script sent to pharmacy for insurance |
| Compounded Options | Limited secondary option in some shortage-affected states | Yes (Primary Focus) |
| Starting Med Price | Pharmacy retail/copay; cash-pay Wegovy from $199/mo (NovoCare intro) | $99 semaglutide / $199 tirzepatide (compounded, all doses flat) |
| Oral Options | Rybelsus (oral semaglutide) | Oral drops & tablets available |
| Geographic Range | All 50 States | All 50 States |
| Onboarding Speed | Same-Day Appointments | Fast (1-3 days, $39 first-month promo) |
At-a-Glance: The 5 Key Differences
- Medication Philosophy: PlushCare still leans heavily toward FDA-approved brand-name medications, but now also supports compounded semaglutide in limited states during shortage periods as a secondary option. Mochi Health continues to offer both brand-name and compounded formulations, with a stronger affordability focus.
- Pricing Model: PlushCare uses a "pay-per-visit" primary care model ($129/visit + $19.99/mo), while Mochi Health uses a flat $79/month membership that includes all provider consultations and dietitian visits, with a $39 first-month promo at the time of update.
- Insurance and Medicare: PlushCare remains one of the few GLP-1 telehealth options that accepts Medicare and works well for insured patients seeking brand-name therapy. Mochi is primarily self-pay for compounded medications, but can send brand-name prescriptions to local pharmacies for patients using insurance.
- Oral GLP-1 Access: PlushCare offers Rybelsus (oral semaglutide) through its primary care model. Mochi has broadened its menu with oral drops and tablets in addition to injectable options.
- Care Model: PlushCare is a comprehensive primary care platform suited to patients who want GLP-1 care inside a broader medical relationship. Mochi is a specialized weight-loss program built around obesity medicine, dietitian support, and flat-rate medication access.
Pricing Comparison: Cash-Pay vs. Insurance
Understanding the "true cost" of GLP-1 therapy requires looking past the monthly membership fee. We analyzed the pricing of both platforms as of July 10, 2026.
The PlushCare Cost Structure
PlushCare’s model is still built primarily for the insured patient. Their 4.6 / 5.0 score and Top Tier designation align with strong Clinical Quality, Support, and Access, but the real-world value depends heavily on whether your insurance covers brand-name treatment.
- Membership: $19.99/month.
- Consultation: $129 per visit (out-of-pocket) or your standard insurance co-pay.
- Medication: Since PlushCare does not dispense medications directly, you pay your pharmacy or pharmacy partner. For insured patients, that may mean a standard co-pay. For cash-pay patients, PlushCare now has more relevance than it did earlier in 2026 because its doctors can prescribe into newer direct-pay pathways:
- Wegovy cash-pay pathway: from $199/month intro pricing for the first two months at lower doses through NovoCare, then $399/month for maintenance.
- Zepbound cash-pay pathway: from roughly $349–$499/month through LillyDirect, depending on dose and availability.
- Rybelsus: available as an oral semaglutide option for patients who prefer tablets over injections.
- Labs: Not included. Patients are generally referred to Quest or LabCorp or may upload recent labs when clinically appropriate.
This matters because PlushCare is no longer just a "good if insurance covers it" option. For some cash-pay patients who specifically want FDA-approved products and are comfortable filling through brand-supported pathways, the economics can look very different than the old $1,000+ retail assumptions.
The Mochi Health Cost Structure
Mochi Health continues to stand out for dose-independent pricing. That flat-rate model is one reason it performs so well in value-oriented comparisons across the GLP-1 Provider Directory.
- Membership: $79/month, with a $39 first-month promo available at the time of this July 2026 update.
- What the membership covers: all provider consultations plus dietitian visits, which simplifies monthly budgeting for patients who want structured support rather than piecemeal scheduling fees.
- Medication (Compounded):
- Semaglutide: $99/month for all doses.
- Tirzepatide: $199/month for all doses.
- All-in monthly cost:
- Semaglutide total: $178/month in a standard month ($79 membership + $99 medication).
- Tirzepatide total: $278/month in a standard month ($79 membership + $199 medication).
- Medication (Brand-Name): If a patient wants FDA-approved Wegovy or Zepbound and has insurance, Mochi can send the prescription to an outside pharmacy for fulfillment at market price, co-pay, or deductible-adjusted cost.
- Labs: Not included in membership, but Mochi can facilitate discounted lab ordering for patients paying out of pocket.
For purely self-pay patients, Mochi’s predictability remains one of its biggest strengths. A patient titrating upward does not see the monthly compounded medication price jump with every dose increase, which is still unusual in this market.
Drugs Available: Brand-Name vs. Compounded
The drug menu is still the biggest fork in the road between these two providers, but the gap has narrowed a bit in 2026 as oral options and shortage-era workarounds have expanded.
PlushCare’s Evolving Menu
PlushCare still centers its GLP-1 program around FDA-approved medications and traditional pharmacy fulfillment. Because it operates as a primary care platform, that approach fits patients who want mainstream prescribing workflows and continuity of care.
- Wegovy (semaglutide): Injection for weight loss.
- Zepbound (tirzepatide): Injection for weight loss.
- Ozempic (semaglutide): Injection for Type 2 Diabetes.
- Mounjaro (tirzepatide): Injection for Type 2 Diabetes.
- Saxenda (liraglutide): Daily injection for weight loss.
- Rybelsus (semaglutide): Daily oral tablet and PlushCare’s clearest oral GLP-1 alternative today.
- Victoza (liraglutide): Daily injection for Type 2 Diabetes.
A notable July 2026 update is that PlushCare has expanded to include compounded semaglutide in limited states during FDA shortage periods as a secondary option. That does not turn PlushCare into a compounding-first clinic, but it does make the platform more flexible for patients who want to stay inside a primary care ecosystem when brand supply is inconsistent.
Mochi Health’s Versatile Menu
Mochi Health still bridges the gap between the premium brand-name market and the more accessible compounded market. Their Top Tier status is supported by broad access, strong support, and unusually high transparency for a platform that serves both brand-name and compounded demand.
- Compounded Semaglutide: Available in all doses for a flat $99/month.
- Compounded Tirzepatide: Available in all doses for a flat $199/month.
- Wegovy & Zepbound: Available for patients who want FDA-approved formulations and can fill through insurance or retail pharmacy channels.
- Oral drops and oral tablets: Available in addition to injections for patients seeking non-injectable options.
That wider menu matters because some patients are not just comparing price. They are comparing delivery format, comfort with injections, and how much they value staying on FDA-approved branded products versus lower-cost compounded alternatives.
According to our 2026 Global GLP-1 Industry Statistics, the ability to stay on a single price point regardless of dose titration is one of the top three factors in long-term patient retention. Mochi’s flat-rate drug pricing remains a major advantage as you move toward higher maintenance doses.
Prescriber Model & Clinical Quality
The "telehealth" label still covers a wide range of medical standards in 2026. Both of these platforms use live video visits, which generally provide more clinical context than text-only intake models. But their care philosophy is very different, and that difference matters as much as headline pricing.
On our official review methodology, both providers sit in the Top Tier category. PlushCare holds a 4.6 / 5.0 Top Tier score, while Mochi Health holds a 4.8 / 5.0 Top Tier score.
Official Score Breakdown: PlushCare
- Clinical: 4.8
- Support: 4.9
- Patient Protection: 4.1
- Cost & Value: 4.8
- Access: 5.0
- Trust & Transparency: 4.5
- Authenticity: 5.0
- Reputation: 3.2
Official Score Breakdown: Mochi Health
- Clinical: 4.8
- Support: 4.9
- Patient Protection: 4.1
- Cost & Value: 4.8
- Access: 4.7
- Trust & Transparency: 5.0
- Authenticity: 5.0
- Reputation: 4.5
PlushCare: The Primary Care Approach
PlushCare’s clinical quality score of 4.8 reflects a broad medical model rather than a narrow weight-loss funnel. During a PlushCare visit, your clinician is not just checking BMI criteria for semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound). They are evaluating your history, current medications, coexisting conditions, and whether your GLP-1 plan should sit inside a broader primary care relationship.
That makes PlushCare especially relevant for patients with hypertension, prediabetes, thyroid history, lipid issues, menopause-related weight gain, or multiple prescriptions that need review together. If you want one telehealth relationship that can handle routine care and GLP-1 follow-up in the same system, PlushCare has a real structural advantage.
Mochi Health: Specialized Bariatric Care
Mochi Health also earns a 4.8 in Clinical Quality, but the reason is different. Its model is built around obesity medicine and sustained weight-management support. Patients are not entering a general primary care practice and then asking for weight-loss help on the side. They are entering a specialized program where GLP-1 therapy, nutrition, follow-up, and affordability are the core product.
The built-in dietitian access matters here. Rapid weight loss can change protein needs, hydration habits, GI tolerance, and muscle-retention strategy. Mochi’s membership includes registered dietitian support as a default part of the care experience, not an optional add-on. That makes it attractive for patients who want a more structured weight-loss program rather than a broader family-medicine relationship.
Telehealth vs. Primary Care Model
This is one of the most important practical differences in the post, because "telehealth GLP-1 care" can mean two very different things.
PlushCare: Telehealth Built on a Primary Care Base
PlushCare behaves like a digital primary care clinic that also prescribes GLP-1s. The upside is depth. If your weight-loss conversation overlaps with blood pressure, lipid management, sleep issues, menopause, or other routine care needs, PlushCare can feel more medically integrated.
That model also tends to appeal to:
- insured patients who want traditional prescribing pathways
- Medicare beneficiaries who need a recognized primary care framework
- patients who prefer local pharmacy fulfillment over direct compounded shipment
- patients who may not yet be sure whether a GLP-1 is the right next step
Mochi Health: Telehealth Built Around Weight Loss
Mochi behaves like a dedicated metabolic health and obesity-care program. The upside is focus. If your main goal is to start and sustain GLP-1 treatment with predictable pricing, recurring support, and nutrition access, Mochi’s model is often simpler.
That model tends to appeal to:
- self-pay patients comparing monthly total cost
- patients comfortable with compounding when appropriate
- people who want direct, ongoing dietitian access
- patients who care more about a specialized weight-loss workflow than a general PCP relationship
Neither model is inherently "better" in every situation. They solve different problems. PlushCare is stronger when your GLP-1 decision sits inside a wider medical picture. Mochi is stronger when your main priority is specialized weight management with clearer cost visibility.
Clinical Quality in the Real World
Both companies score well clinically, but patients should still think beyond the score headline.
With PlushCare, the big practical advantage is care continuity. A clinician who understands your broader chart may be better positioned to evaluate contraindications, medication interactions, and non-GLP-1 contributors to weight gain. That is especially useful if your care goals include more than weight loss alone.
With Mochi, the practical advantage is repetition and specialization. When a practice spends a large portion of its time managing GLP-1 titration, side effects, adherence issues, and dietitian-guided follow-up, that focus can improve the day-to-day patient experience for straightforward obesity treatment.
In short: PlushCare offers breadth; Mochi offers specialization. Both can be high-quality choices, but the right fit depends on what kind of clinical relationship you want.
Patient Flow: From Sign-up to Injection
How fast can you start? In 2026, supply chain issues remain a factor, but onboarding speed has improved across the board.
The PlushCare Onboarding Experience
- Selection: You choose your preferred medication (Wegovy, Zepbound, etc.).
- Booking: You book a same-day or next-day video appointment.
- Consultation: You meet your doctor to discuss history and goals.
- Prior Authorization: PlushCare’s dedicated team works with your insurance to get the medication covered.
- Pharmacy: Once approved, the prescription is sent to your local pharmacy.
The Mochi Health Onboarding Experience
- Intake: A 3-minute eligibility quiz covers your BMI and health history.
- Account Setup: You select a membership plan (monthly or multi-month).
- Video Visit: You schedule a video visit with a provider to confirm eligibility.
- Dietitian Visit: You meet with a registered dietitian to build a nutrition plan.
- Shipment: Compounded medication is shipped directly to your door from a verified 503A/503B pharmacy.
For a deeper look at how this compares to other market leaders, see our review of Ivim Health.
Geographic Availability & Access
Both platforms have navigated the complex 2026 regulatory landscape to offer nationwide coverage.
- PlushCare: Available in all 50 states. Their same-day appointment availability remains a standout feature, which is consistent with their 5.0 Access sub-score on the official review page.
- Mochi Health: Available in all 50 states for telehealth and medication fulfillment pathways, with a 4.7 Access sub-score. Their logistics network is still efficient, and onboarding is commonly quoted in the 1–3 day range, with compounded shipments generally following provider approval.
Customer Service & Reputation
A platform’s reputation is often where the reality of the patient experience lives.
PlushCare has a Reputation score of 3.2. While their clinical standards are high, they have faced criticism on Trustpilot (3.4 rating) regarding billing and scheduling hiccups.
Mochi Health holds a much higher Reputation score of 4.5. With a 4.4 Trustpilot rating across more than 15,000 reviews, Mochi has demonstrated an ability to scale while maintaining high patient satisfaction.
Refund Policy & Protections
Both providers have a 4.1 Patient Protection sub-score on their official review pages, which puts them in a fairly typical range for this category rather than far above the field.
- PlushCare: Generally does not refund visit fees once the consultation has occurred. Membership can be canceled at any time.
- Mochi Health: Membership and medication refund terms should always be reviewed at checkout, especially when promotional first-month pricing is active. Medication costs are typically non-refundable once dispensed or shipped.
How Each Provider Handles the FDA’s Evolving Compounding Landscape
The compounding environment remains one of the biggest moving targets in 2026, especially around semaglutide and tirzepatide availability during and after shortage-related periods.
PlushCare’s Position
PlushCare still presents as a brand-first medical platform. That means its default posture is toward FDA-approved commercial products filled through standard pharmacy channels. The July 2026 nuance is that PlushCare has expanded into limited compounded semaglutide access in certain states during shortage periods. For patients, that means PlushCare is somewhat more adaptive than it used to be, but compounding is still not the center of the model.
This approach may appeal to patients who:
- prefer branded therapy first
- want compounded medication only as a backup during shortage disruption
- are uncomfortable using a provider whose business model depends heavily on compounding
Mochi Health’s Position
Mochi is much more directly exposed to the compounding conversation because affordable compounded access is core to its value proposition. The platform’s strength is that it has built a patient experience around transparent pricing, telehealth follow-up, and pharmacy compliance signaling rather than treating compounding as an afterthought.
For patients, the practical takeaway is simple: if the FDA environment shifts, Mochi’s model is more likely to be affected because compounding is a larger part of the business. But if compounded access remains available under the relevant rules and enforcement environment, Mochi remains one of the clearest self-pay affordability plays in the category.
The right question is not "Is compounding good or bad?" The right question is whether you want a brand-first fallback approach like PlushCare or a compounding-integrated affordability model like Mochi.
The Oral GLP-1 Landscape in 2026
Oral GLP-1 demand has increased because not every patient wants an injectable, and not every patient wants to start with a weekly pen. That does not mean oral therapy is interchangeable with injectables, but it does mean provider flexibility matters more now.
PlushCare and Oral GLP-1s
PlushCare’s clearest oral option is Rybelsus (oral semaglutide). For patients who prefer a traditional pharmacy prescription and a mainstream primary care workflow, that is a meaningful advantage. It gives PlushCare an answer for patients who want to explore oral treatment without moving into a compounded-first ecosystem.
PlushCare may also be relevant for patients tracking newer oral-category developments such as Foundayo or future Wegovy pill conversations, because its primary care model is naturally aligned with mainstream prescription adoption as those options mature.
Mochi and Oral GLP-1s
Mochi has responded differently by broadening the menu with oral drops and oral tablets in addition to injections. That creates a wider set of non-injectable entry points for self-pay patients, though patients should still ask detailed questions about formulation type, expected efficacy, fulfillment pathway, and whether they are receiving a brand-name or compounded product.
What This Means for Buyers
If you want an FDA-approved oral semaglutide product today, PlushCare’s Rybelsus pathway is the cleaner fit. If you want a broader menu of oral-style alternatives inside a specialized weight-loss program, Mochi offers more variety.
"Best For" Scenarios
Because we do not declare a single "winner," we have identified the specific scenarios where one provider stands out based on our weighted methodology and each platform’s current July 2026 positioning.
Best for insured or Medicare patients who want FDA-approved brands with real primary care depth: PlushCare
If you have commercial insurance or Medicare and want a clinician who can work through standard pharmacy and prior-authorization channels while also functioning as a real primary care touchpoint, PlushCare is the stronger fit. Its model makes the most sense for patients who value FDA-approved brands, broader medical continuity, and established care workflows.
Best for cash-pay patients who want flat-rate pricing, dietitian access, and compounded affordability: Mochi Health
If your top priority is a predictable monthly bill, Mochi remains one of the strongest self-pay options in the category. The flat-rate compounded pricing, bundled provider access, and included dietitian support make it especially appealing for patients who know they will be paying out of pocket.
Best for comprehensive health management: PlushCare
If you want a clinician who can discuss your weight, blood pressure, menopause symptoms, cholesterol, refills, and routine primary care needs in one ecosystem, PlushCare has a clear structural advantage over a weight-loss-only platform.
Best for nutritional support and structured obesity care: Mochi Health
Weight loss is about more than the prescription itself. Mochi’s built-in dietitian access and obesity-focused workflow make it a strong choice for patients who want recurring, specialized support rather than a one-off prescribing relationship.
Best for oral GLP-1 seekers
This scenario depends on what you mean by "oral." If you want Rybelsus, which is oral semaglutide prescribed through a more conventional medical pathway, PlushCare is the better fit. If you want a broader menu of non-injectable options such as oral drops and tablets inside a specialized weight-loss program, Mochi offers more variety.
Best for patients navigating the compounding shortage
If you want a brand-first approach with limited compounded semaglutide flexibility during shortage periods, PlushCare is the more conservative option. If you want a provider built around compounded affordability and ongoing self-pay access, Mochi is more aligned with that use case. The right answer depends on your comfort with compounding, your budget, and how important FDA-approved brand continuity is to you.
Frequently Asked Questions (FAQ)
Is Mochi’s $39 first month still available?
At the time of this July 10, 2026 update, Mochi is promoting a $39 first-month membership offer. Because promotional pricing can change quickly, patients should confirm the current offer on the checkout or pricing page before enrolling.
Does PlushCare offer compounded semaglutide?
PlushCare is still primarily a brand-name-focused provider, but as of July 2026 it has expanded to include compounded semaglutide in limited states during FDA shortage periods as a secondary option. That is different from a compounding-first model and may not be available in every state or every clinical situation.
What is PlushCare’s approach to compounded medications during shortages?
PlushCare appears to treat compounded medication as a limited fallback rather than the core program. Patients who want FDA-approved brands first, but who also want some flexibility during shortage disruption, may find that balance appealing.
Does Mochi Health offer only injections?
No. Mochi now offers oral drops and oral tablets in addition to injectable programs. Patients should still confirm exactly which formulation they are being prescribed, whether it is compounded or brand-name, and how it is fulfilled.
What oral GLP-1 options are available at each provider?
PlushCare offers Rybelsus (oral semaglutide) as its clearest oral option. Mochi offers oral drops and oral tablets alongside injectables. Patients comparing oral options should ask about formulation, expected outcomes, cost, and whether the product is FDA-approved or compounded.
Is Mochi Health LegitScript certified?
Mochi Health’s own pages (read 7, 8 and 13 October 2026) make no claim to LegitScript certification. LegitScript’s directory is behind a captcha, so we have not checked it.
Can I use my own labs with PlushCare and Mochi?
Yes, both platforms generally allow patients to upload recent labs when clinically appropriate, which can reduce repeat testing costs. If you do not have recent lab work, both can typically facilitate new lab orders.
Which is faster to start?
PlushCare typically offers same-day video appointments, making it one of the faster ways to start a brand-name prescription pathway. Mochi is also fast, commonly onboarding patients within 1–3 days, and the active first-month promo may make that trial period more appealing for self-pay shoppers.
Does Medicare cover GLP-1s through PlushCare?
PlushCare can accept Medicare for the visit side of care, but whether the medication is covered depends on your specific Part D plan, diagnosis, and formulary rules. Patients should verify both provider visit coverage and pharmacy benefit coverage separately.
Internal References
- GLP-1 Provider Directory : Compare 76 reviewed providers.
- Ivim Health Review : A leading provider review for patients comparing specialized GLP-1 care.
- 2026 GLP-1 Industry Report : Data on pricing trends and medication supply.
- cheapest GLP-1 programs : A cost-focused look at lower-priced GLP-1 options.
- best overall GLP-1 brands : A broader comparison of leading GLP-1 medication brands and programs.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any medication.
Considering a compounded GLP-1 program? Read is TrimRx legit first.
Considering this provider? Read our Ivim Health review for cost, screening, and the full breakdown.
Corrected 9 October 2026. We removed 3 generated images from this article. Generated images on this site no longer show certifications, organisations, products, prices or figures unless the specific claim has been checked.
Corrected 13 October 2026. This article said Mochi Health claims LegitScript certification. Mochi’s own pages (read 7, 8 and 13 October 2026) make no such claim, so that has been removed. The claim came from our earlier Mochi review.
Corrected 14 October 2026: this article previously gave Better Business Bureau ratings for providers it compares, taken from our April 2026 research. We kept no record of where those ratings came from, so they have been removed.
Keep exploring our GLP-1 resources:
